Heyholder
‹ Activism Filings

Dong-A Pharmaceutical Co.,Ltd. Q3 operating profit KRW 35.1 billion, up 5.4% from a year earlier

Dong-A Pharmaceutical Co.,Ltd.· Periodic Report

AI summary · Not investment advice

In Q3, the company sold KRW 431.0 billion and earned KRW 35.1 billion from its main business, up 5.4% from a year earlier and down 9.9% from the prior quarter.

Operating profit · 3 months

KRW 35.1 billion

Key facts

Revenue (3 months)
KRW 431.0 billion
Net income (3 months)
KRW 32.1 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 382.6 billion
Revenue (year to date)
KRW 1.2 trillion
Operating profit (prior-year 3 months)
KRW 33.3 billion
Operating profit (year to date)
KRW 93.2 billion
Net income (prior-year 3 months)
KRW 47.1 billion
Net income (year to date)
KRW 81.5 billion

Commentary

AI commentary · Not investment advice

What happened

Dong-A Pharmaceutical filed its quarterly report for the third quarter on a consolidated basis. Sales for the latest 3 months were KRW 431.04 billion. That is 12.7% higher than the same 3 months a year earlier and 4.5% higher than the previous quarter.

In the company's terms

Operating profit (money earned from the core business) for the 3 months was KRW 35.10 billion. It rose 5.4% from a year earlier and fell 9.9% from the previous quarter.

What changes for shareholders

Net income (the final profit left after taxes and other costs) for the 3 months was KRW 32.13 billion. It fell 31.8% from a year earlier and rose 11.2% from the previous quarter.

For January through September combined, sales were KRW 1,194.43 billion. Operating profit was KRW 93.19 billion and net income was KRW 81.53 billion.

Comments

No comments yet

Comments from shareholders will appear here.